

1 **Optimised methods for the targeted surveillance of extended-spectrum**  
2 **beta-lactamase producing *Escherichia coli* in human stool**

3  
4 **Sarah Gallichan<sup>1</sup>, Sally Forrest<sup>1</sup>, Esther Picton-Barlow<sup>1</sup>, Claudia McKeown<sup>1</sup>,**  
5 **Maria Moore<sup>1</sup>, Eva Heinz<sup>1,2</sup>, Nicholas A Feasey<sup>1, 4</sup>, Joseph M Lewis<sup>1,3</sup>, Fabrice E**  
6 **Graf<sup>1, \*</sup>**

7  
8 <sup>1</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool,  
9 UK

10 <sup>2</sup>Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK

11 <sup>3</sup>Department of Clinical Infection, Microbiology & Immunology, University of Liverpool,  
12 Liverpool, UK

13 <sup>4</sup>The School of Medicine, University of St Andrews, St Andrews, UK

14  
15 **Keywords**

16 Molecular epidemiology; Antimicrobial resistance; Transmission; Surveillance;  
17 Microbiological methods; DNA extraction

18  
19 **\*Correspondence:**

20 Fabrice Graf

21 Liverpool School of Tropical Medicine

22 Pembroke Place

23 Liverpool, UK

24 **Abstract**

25 Understanding transmission pathways of important opportunistic, drug resistant  
26 pathogens, such as extended-spectrum beta-lactamase (ESBL) producing  
27 *Escherichia coli*, is essential to implementing targeted prevention strategies to  
28 interrupt transmission and reduce the number of infections. To link transmission of  
29 ESBL-producing *E. coli* (ESBL-EC) between two sources, single nucleotide resolution  
30 of *E. coli* strains as well as *E. coli* diversity within and between samples is required.  
31 However, the microbiological methods to best track these pathogens are unclear. Here  
32 we compared different steps in the microbiological workflow to determine the impact  
33 different pre-enrichment broths, pre-enrichment incubation times, selection in pre-  
34 enrichment, selective plating, and DNA extraction methods had on recovering ESBL-  
35 EC from human stool samples, with the aim to acquire high quality DNA for sequencing  
36 and genomic epidemiology. We demonstrate that using a 4-hour pre-enrichment in  
37 Buffered Peptone Water, plating on cefotaxime supplemented MacConkey agar and  
38 extracting DNA using Lucigen MasterPure DNA Purification kit improves the recovery  
39 of ESBL-EC from human stool and produced high-quality DNA for whole genome  
40 sequencing. We conclude that our optimised workflow can be applied for single  
41 nucleotide variant analysis of an ESBL-EC from stool.

## 42 **Introduction**

43 The spread of antimicrobial resistance (AMR) in bacterial pathogens is a global threat  
44 to public health. Of particular concern are infections caused by extended-spectrum  
45 beta-lactamase (ESBL) producing *Escherichia coli*, which is on the World Health  
46 Organisations (WHO) priority AMR pathogen list<sup>1</sup>. ESBL-producing *E. coli* (ESBL-EC)  
47 are resistant to aminopenicillins and 3rd-generation cephalosporin (3GC) antibiotics,  
48 which are commonly used to treat infections caused by Gram-negative bacteria.  
49 ESBL-EC infections can result in a higher mortality and longer hospital stays and may  
50 require access to reserve antibiotics such as carbapenems<sup>2-4</sup>.

51

52 Infection prevention is preferable to cure and will concurrently reduce antibiotic use.  
53 To prevent the acquisition of enteric pathogens in care facilities, it is critical to  
54 understand their transmission pathways. This is challenging for near ubiquitous  
55 organisms such as *E. coli*, which are frequently part of a healthy gut flora and can also  
56 be opportunistic pathogens<sup>5</sup>. Typically, human faecal samples have been shown to  
57 contain one to three different *E. coli* genotypes at any one time<sup>6</sup> although as many as  
58 nine or more different *E. coli* genotypes per stool sample have been described<sup>7</sup>. The  
59 number of multidrug resistant *E. coli* strains detected has also been shown to increase  
60 with host age<sup>8</sup>. Therefore, differentiating intraspecies diversity of different *E. coli*  
61 strains requires comparisons at single nucleotide variation (SNV) resolution<sup>9</sup>. To track  
62 transmission events of ESBL-EC in care settings, microbiological methods need to  
63 capture the within-host diversity of ESBL-EC within and between different samples  
64 accurately and cost-effectively, even when present at low levels. Consensus on which  
65 microbiological methods are optimal and a comprehensive comparison of the impact  
66 of different microbiological methods are currently lacking.

67


68 Currently, the most common healthcare diagnostic method of ESBL-EC isolation from  
69 human stool is direct plating on cefotaxime-supplemented MacConkey or  
70 chromogenic agar and confirming the production of ESBL using the double disk  
71 diffusion method<sup>10,11</sup>. This is often followed by molecular investigation of ESBL  
72 resistance genes via multiplex PCR<sup>12,13</sup>. While these methods are effective in  
73 identifying the presence of an ESBL-EC to inform treatment options, they lack the  
74 resolution to infer transmission because they do not allow us to clearly distinguish  
75 between closely related *E. coli*<sup>14</sup>. The distinction between two different clades within  
76 the same ST of *E. coli* can be as little as 70 nucleotides, therefore cannot be accurately  
77 distinguished using PCR methods<sup>15</sup>.

78

79 Surveillance studies focused on describing transmission pathways pre-enrich samples  
80 with low microbial load, i.e., from rectal swabs, to increase detection of present ESBL-  
81 EC<sup>16,17</sup>. Combined with whole-genome sequencing (WGS) this allows for accurate  
82 clustering of isolates at SNV resolution. However, there is little consensus between  
83 studies, or data on controlled comparisons, on the impact of pre-enrichment broth,  
84 pre-enrichment duration, selective agar, and method of DNA extraction has on sample  
85 diversity. Here, we describe an optimized approach for targeted surveillance of ESBL-  
86 EC from human stool samples at SNV resolution to inform transmission modelling with  
87 the potential to capture within-host diversity.

88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111

## Methods



112 **Figure 1** *Graphical summary of the main research questions and comparisons performed for each step of the microbiological*  
113 *processing of ESBL-EC from stool*

114 **ESBL-EC growth dynamics in different pre-enrichment broths**

115 Pre-enrichment broths (Brain-Heart Infusion, Tryptic Soy, Buffered Peptone Water and  
116 Davis Minimal) commonly used in the recovery of ESBL-EC from clinical sources were  
117 selected for comparison in this study. These pre-enrichment broths were prepared  
118 according to the manufacturer's recommendations (**Supplementary Table 1**). We  
119 used three reference strains encoding ESBLs: NCTC 13341 (*bla<sub>CTX-M-15</sub>*); NCTC 13476  
120 (*bla<sub>IIMP</sub>*); NCTC 13846 (*bla<sub>CTX-M-27</sub>*), with the latter also encoding plasmid-derived  
121 colistin resistance (**Supplementary Table 2**). We further included a clinical isolate,  
122 CAB17W, encoding *bla<sub>CTX-M-15</sub>* (**Supplementary Table 2**). The growth of single ESBL-  
123 EC isolates in different pre-enrichment broths was determined to establish growth  
124 dynamics. Growth of the reference ESBL-EC (NCTC 13441) in four pre-enrichment  
125 broths (BPW, DM, BHI, and TS) was monitored every 10 minutes through regular  
126 optical density readings at 600 nm wavelength in the CLARIOstar plate reader (BMG  
127 Labtech, Ottenberg, Germany) for 24 h. A population logistic model was fitted to the  
128 resulting data with the Growthcurver package<sup>18</sup>. The recovery of *E. coli* from different  
129 pre-enrichment broths with varying incubation times was tested. *E. coli* (NCTC 13441)  
130 was inoculated (approximately  $2 \times 10^7$  CFU/mL) into 5 mL of four pre-enrichment  
131 broths (BPW, DM, BHI, and TS) and grown shaking at 37 °C and 220 rpm. After 2, 4,  
132 6 and 8 hours, 1:10 serial dilutions of each pre-enrichment culture were performed  
133 and dilutions  $10^{-4}$  to  $10^{-12}$  were spotted onto LB agar and incubated at 37°C overnight.  
134 The following day, the number of colony forming units (CFUs) recovered from each  
135 broth was calculated.

136 Stool was collected from three healthy volunteers, defined as individuals not using  
137 antibiotics or experiencing any gastrointestinal problems. The stool was resuspended  
138 in a stool diluent solution (1:5 w/v) prepared according to the maltodextrin-trehalose

139 method with the addition of 10% glycerol <sup>19</sup>. The stool slurry was mixed using a  
140 magnetic stirrer for 15 minutes and allowed to sediment for 5 minutes. Supernatants  
141 from each of the three stool slurries were mixed in equal proportions and stored in  
142 cryotubes at - 80 °C. Before use in experiments, the stool slurry was rapidly thawed in  
143 a water bath at 37°C for 10 minutes and vortexed thoroughly. To determine the optimal  
144 pre-enrichment broth and incubation time for the recovery of ESBL-EC from stool, a  
145 spiked stool model was developed using 1 mL of the pooled stool slurry and a 1 µL  
146 spike of the NCTC 13441 or CAB17W (approximately 1 x 10<sup>5</sup> CFU/mL). The ESBL-  
147 non-producing *E. coli* strain (NCTC 12241) was used as a negative control to  
148 determine if the antibiotic supplement sufficiently inhibited growth. The spiked stool  
149 models were pre-enriched using TS and BPW with and without the addition of  
150 selection (1 µg/ mL cefotaxime) and incubated for 4 and 18 hours, shaking at 37 °C  
151 and 220 rpm. Following incubation, 1:10 serial dilutions of each pre-enrichment culture  
152 were made and dilutions (10<sup>-4</sup> to 10<sup>-7</sup> for the 4-hour incubation and 10<sup>-5</sup> to 10<sup>-8</sup> for the  
153 18-hour incubation) were plated onto LB agar and CHROMagar in 10 µL spots and  
154 incubated at 37 °C overnight. The number of CFUs recovered from each broth was  
155 calculated.

156

### 157 **Recovery of ESBL-EC using different selective agars**

158 Selective agar (MacConkey, Membrane Lactose Glucoronide Agar (MLGA) and  
159 CHROMagar) commonly used in the recovery of ESBL-EC from environmental, clinical  
160 and food sources were selected for comparison in this study. These selective agars  
161 were prepared according to the manufacturer's recommendations (**Supplementary**  
162 **Table 1**). MacConkey and MLGA agars were supplemented to a final concentration of  
163 1 µg/mL cefotaxime (Melford, Suffolk, UK). To assess the recovery of ESBL-EC from



164 stool using selective agar, the stool spike model described above was used. The  
165 spiked stool was pre-enriched in BPW for 4 hours, shaking at 37°C and 220 rpm.  
166 Following incubation, 1:10 serial dilutions of each spiked stool sample were made, and  
167 10<sup>-4</sup> to 10<sup>-7</sup> dilutions were plated onto MacConkey agar, CHROMagar and MLGA  
168 plates in 10 µL spots and incubated at 37 °C overnight. The number of CFUs  
169 recovered from each selective agar was calculated.

170

#### 171 **Limit of ESBL-EC detection with pre-enrichment compared with direct plating**

172 A series of 100 µL of CAB17W ranging from 1 CFU/mL to 1 x 10<sup>8</sup> CFU/mL was spiked  
173 into 100 µL of stool slurry. The spiked stools were serially diluted (1:10) and 10 µL of  
174 each dilution was spotted onto cefotaxime supplemented MacConkey agar and  
175 incubated at 37 °C overnight. A 96 deep well plate was then inoculated with 10 µL of  
176 the remaining stool spikes in 1 mL of BPW, this was done in triplicate for each spike  
177 input concentration. The deep well plate was then sealed with a breathable sealing  
178 membrane and placed in an Innova 42R 19 mm Orbit shaking incubator set at 37 °C  
179 and 220 rpm. After 4 hours the plate was removed from the incubator, each well was  
180 again diluted in series 1:10 and spots of 10µL were plated onto cefotaxime  
181 supplemented MacConkey and incubated at 37°C overnight. The number of CFUs  
182 recovered were then calculated.

183

#### 184 **DNA extraction kit comparison**

185 A single colony of each of four *E. coli* strains (**Supplementary Table 2**: NCTC 13441,  
186 NCTC 13476, NCTC 13846, CAB17W) were inoculated in 5 mL of LB with and grown  
187 overnight. Then, cultures were diluted to an OD600 of 2 (~ 2 x 10<sup>9</sup> CFU/mL). The cells  
188 were washed three times in phosphate-buffered saline (PBS). The resulting pellets

189 were resuspended in 1 mL of PBS and split into three tubes with 250  $\mu$ L and used as  
190 the input for each extraction method. To assess the yield, quality, efficiency, and cost  
191 of five commercially available kits (**Supplementary Table 1**) and a simple boiling  
192 method<sup>20</sup>, we extracted DNA from each of the four *E. coli* isolates in technical  
193 triplicates (n=12 for each extraction method), with three experimental replicates (n=36  
194 extractions per method) on different days. The DNA yield was then measured using  
195 the Qubit 4 Fluorometer (Agilent Technologies, California, USA) and the Agilent  
196 TapeStation System 4150 (Agilent Technologies, California, USA) was used to  
197 determine the DNA integrity. The DNA quality was assessed by measuring the  
198 A260/230 and A260/280 absorbance ratios using the NanoPhotometer (Implen,  
199 California, United States). Scores (**Supplementary Table 3**) were allocated according  
200 to the criteria in **Supplementary Table 4**. Each DNA extraction method was then  
201 ranked according to the score given, from highest (1) to lowest (6) performing in each  
202 category: DNA yield, DNA quality, cost, hands-on time, ease of protocol and total  
203 protocol time.

204

### 205 **Single nucleotide variant analysis**

206 To determine whether our protocol would provide sufficient resolution for the detection  
207 of single nucleotide variants in a stool sample, we processed a spiked stool sample  
208 and an ESBL-EC positive rectal swab. For the spiked stool sample, we inoculated 10  
209  $\mu$ L of a 100-fold diluted overnight CAB17W culture ( $\sim 8 \times 10^7$  CFU/mL) into 1 mL of  
210 the pooled stool slurry, vortexed the mixture thoroughly and added 100  $\mu$ L to 5 mL of  
211 BPW in a 15 mL Falcon tube. The ESBL-EC positive rectal swab was obtained with  
212 permission from a participant in an observational cohort study of faecal ESBL carriage  
213 in hospital patients and care home residents across Liverpool, UK. The rectal swab

214 was placed directly in 5 mL of BPW in a 15 mL Falcon tube. Falcon tubes were  
215 incubated for 4 hours at 37 °C, shaking at 220 rpm. After 4 hours, 100 µL of the culture  
216 was spread on cefotaxime supplemented (1 µg/mL) MacConkey agar and incubated  
217 at 37 °C overnight. The following day, we picked 7 single colonies, restreaked each  
218 colony on another cefotaxime supplemented MacConkey agar and incubated at 37 °C  
219 overnight. DNA was then extracted from each of the purified colonies using the  
220 MasterPure Complete DNA and RNA Purification Kit (Lucigen, Wisconsin, USA)  
221 according to the manufacturer's recommendations. The DNA concentrations were  
222 then measured using the Qubit 4 Fluorometer (Agilent Technologies, California, USA)  
223 and the DNA sent for whole-genome sequencing using the NovaSeq platform (Illumina  
224 Inc, California, USA) at Azenta Life Sciences (Frankfurt, Germany). Sequence data  
225 (reads) were obtained as fastq files. Sequencing adaptors were removed from the  
226 reads using Trimmomatic version 0.39<sup>21</sup> and the quality of the trimmed reads was  
227 assessed using the quality metrics provided by FastQC version 0.11.9<sup>22</sup>. ARIBA<sup>23</sup> was  
228 used to call the AMR genes using the CARD database<sup>24</sup> and to determine ESBL-EC  
229 multilocus sequence type as defined by the seven-gene Achtman scheme<sup>25</sup> hosted at  
230 pubMLST (<https://pubmlst.org/>). Single nucleotide variants (SNVs) were called  
231 between the relevant reference genome (ST167: GCF\_025398915.1; ST131:  
232 GCF\_004358405.1; ST1193: GCF\_003344465.1) and the single pick sequences  
233 using snippy version 4.3.6 (<https://github.com/tseemann/snippy>). We then generated  
234 a core genome alignment of all the single pick sequences using snippy-core (with  
235 default settings). All non-nucleotide characters and potentially recombinant sequence  
236 regions were removed from the multisequence alignment using the snippy-  
237 clean\_full\_aln and Gubbins version 2.3.4<sup>26</sup> respectively. We then extracted the SNVs  
238 from the cleaned multisequence alignment using snp-sites (using the -c option) and

239 created a pairwise SNV distance comparison between each single pick sequence  
240 using snp-dists version 0.8.2 (<https://github.com/tseemann/snp-dists>).

241

## 242 **Statistical analysis**

243 Measurements were summarised as mean and standard deviation or 95% confidence  
244 interval, calculated as one standard deviation above and below the mean value. Box-  
245 and-whisker plots, where presented, show medians as a horizontal line, 25th and 75th  
246 centiles as boxes, and at most 1.5 times interquartile range as whiskers. Analysis of  
247 variance (ANOVA) tests were used to determine the significance of any observed  
248 differences between groups.  $P < 0.05$  was considered statistically significant and,  
249 where appropriate,  $P$  values were adjusted for multiple comparisons using the  
250 Bonferroni correction. A post-hoc Tukey test was used for pairwise sample  
251 comparisons when ANOVA tests were significant. All statistical analysis was  
252 performed using R version 4.1.3<sup>27</sup>. All R code is accessible from our Github repository  
253 ([https://github.com/SarahGallichan/ESBL-EC\\_methods.git](https://github.com/SarahGallichan/ESBL-EC_methods.git))

254

## 255 **Results**

### 256 **ESBL-EC recovery using different pre-enrichment conditions and selective** 257 **agars**

258 We assessed the growth dynamics of two ESBL-EC strains (NCTC 13441 and  
259 CAB17W) in different pre-enrichment broths to determine the optimal incubation time  
260 for recovery of bacteria in log growth phase (**Supplementary Figure 1**). To summarise  
261 the dynamics of the resulting growth curves, the data was fitted to a population logistic  
262 model (**Supplementary Table 5**). ESBL-EC reached midpoint of log-phase after  
263 approximately 4 hours in BHI, TS, and DM; and after approximately 7 hours in BPW.


264 Therefore, we chose incubation times of between 2 and 8 hours to quantify ESBL-EC  
265 recovery from different broths and assessed bacterial count in CFU from each broth  
266 after 4 incubation time points (2, 4, 6 and 8 hours). Across all 4 time points, BHI  
267 resulted in the highest and DM the lowest *E. coli* recovery (**Supplementary Figure 2**).  
268 We performed pair-wise broth comparisons at each time point. There was no  
269 significant difference between *E. coli* growth in BHI, BPW and TS across all 4 time  
270 points (**Supplementary Table 6**). However, *E. coli* counts in DM was significantly  
271 lower than BHI and BPW after 2 hours; BHI, BPW and TS after 4 hours; and BHI and  
272 TS after 8 hours of incubation. The largest increase in amount of *E. coli* CFU recovered  
273 between the two time points for each broth was from 2 to 4 hours of incubation  
274 (**Supplementary Table 6**), which is within the log growth phase of *E. coli* in each broth.  
275 Therefore, we selected 4 hours of incubation to investigate the growth of ESBL-EC  
276 from spiked stool.


277

278 We selected TS (a high nutrient broth with multiple amino acid sources) and BPW (a  
279 low nutrient broth with one amino acid source) for the spike experiments, adding  
280 defined amounts of ESBL-EC (NCTC 13441 and CAB17W) to stool samples. Donated  
281 stool was confirmed to have no growth of cefotaxime (a 3GC) resistant bacteria by  
282 plating on 1µg/mL cefotaxime supplemented MacConkey. We assessed the recovery  
283 of these spiked strains, testing whether the addition of selection with cefotaxime and  
284 the length of incubation time influenced the concentration of spiked ESBL-EC strains  
285 we were able to recover (**Figure 2**). After 4 hours of incubation, there was no  
286 significant difference in CAB17W growth (i.e. CFU concentration) between TS and  
287 BPW and whether antibiotic was supplemented or not. However, at 4 hours the growth  
288 of NCTC 13441 in the TS without antibiotic supplement was 2.75 CFU/mL (CI: 2.28 –

289 3.33,  $p = 0.0004$ ) more than in BPW without supplement, while there was no significant  
290 difference between the growth in either broth at 4 hours when supplemented with  
291 cefotaxime.

# CAB17W spiked into stool





**Figure 2** Growth of reference (NCTC 13441) and clinical (CAB17W) ESBL-EC spiked into human stool under different pre-enrichment conditions. The spiked stool models were pre-enriched in different broths (Buffered Peptone Water and Tryptic Soy) for incubation times (4-hour and 18-hour), with and without the addition of the antibiotic cefotaxime.

292

293 At 18 hours the effects of the addition of cefotaxime and broth on growth were different

294 for each strain. Antibiotic supplement significantly increased the recovery of NCTC



295 13441 after 18 hours compared to no supplementation in TS, by 100.78 CFU/mL (CI:  
296 39.81 – 251.19,  $p = 0.01$ ). There was no significant difference in growth of NCTC  
297 13441 at 18 hours between TS and BPW. However, recovery of CAB17W was  
298 significantly higher in BPW after 18 hours of incubation compared to TS, by a  
299 difference of 68 CFU/mL (CI: 51.11 – 91.26,  $p = 0.0001$ ) with antibiotic supplement  
300 and 41.16 CFU/mL (CI: 33.15 – 51.10,  $p < 0.0001$ ) without an antibiotic supplement.  
301 While an 18-hour pre-enrichment in antibiotic supplemented broth best recovered the  
302 highest CFU/mL for both NCTC 13441 and CAB17W, there were inconsistencies  
303 between broths depending on the strain. Therefore, we concluded that a 4-hour pre-  
304 enrichment in BPW was better for a more consistent increase in both ESBL-EC strains  
305 without requiring an antibiotic supplement.

306 Next, we then compared ESBL-EC recovery on three different ESBL-EC selective  
307 agars (CHROMagar, MLGA and MacConkey) from our stool spike models. ESBL-EC  
308 was recovered from all agars, with no significant differences in CFU/mL  
309 **(Supplementary Table 8)**. However, there was a clear difference in the cost per  
310 sample of each selective agar, with MacConkey being the most cost-effective and  
311 CHROMagar being the most expensive **(Supplementary Table 1)**.


312

313 The limit of ESBL-EC detection from CAB17W spiked stool was then determined for  
314 4-hour pre-enrichment in BPW and compared with directly plating on cefotaxime  
315 supplemented MacConkey. Overall, the mean difference in ESBL-EC recovery  
316 between 4-hour pre-enrichment in BPW and direct plating was 47 CFU/mL (CI: 9.65 –  
317 233.08,  $p < 0.001$ ) **(Supplementary Figure 3)**. The limit of detection using direct  
318 plating was 1.91 CFU/mL and with a 4-hour pre-enrichment, the limit of detection  
319 improved to 0.05 CFU/mL.

320

321 **Large variability in yield and quality of DNA using different extraction methods**

322 DNA from the same input concentration of four different *E. coli* strains  
323 **(Supplementary Table 2)** was extracted using five commercially available kits **(Table**  
324 **3)** and a simple boiling method. The DNA yield was measured using the Qubit  
325 fluorometer **(Figure 3)**. The boiling method resulted in the highest mean DNA yield  
326 overall for the Qubit (16.66 ng/mL, 95% CI: 16.16 – 17.16) while the DNeasy kit  
327 resulted in the lowest (3.28 ng/mL; 95% CI: 4.28 – 2.28) **(Figure 3)**.



**Figure 3** DNA yield from the six extraction methods measured using the Qubit. Technical (each sample extracted in triplicates) and experimental replicates (each extraction method performed three separate times) are plotted for each extraction kit ( $n = 36$ ). The outliers are shown as points outside of the boxplot whiskers.

328

329 The DNA quality was assessed using the A260/280 absorbance ratio. Downstream  
330 applications requiring high quality DNA, such as short-read and especially long-read  
331 sequencing platforms, require that the A260/A280 absorbance ratio is in the range

332 between 1.8 to 2.1. The Promega Wizard kit and the DNeasy kit had the largest  
 333 proportion of technical and experimental replicates (67%) within this range while the  
 334 Zymo Miniprep kit had the lowest proportion (11%) (**Figure 4A**). Additionally, the DNA  
 335 integrity was assessed with the DNA Integrity Number (DIN), which is a numerical  
 336 assessment (1 to 10) of the DNA integrity determined by the TapeStation system  
 337 algorithm. A DIN score of 1 indicated very degraded DNA and DIN 10 indicated highly  
 338 intact DNA. The Lucigen MasterPure and the Zymo miniprep kits had the highest DIN  
 339 followed closely by the Promega Wizard (**Table 1**).

340

341 **Table 1** Mean of measurements (technical and experimental replicates averaged  
 342 across three independent experiments) for each DNA extraction method, including  
 343 the 95% confidence intervals, for the tested *E. coli* and proportion (percentage of  
 344 technical replicates) within defined absorbance ratio range.



345

	Boiling	DNeasy	Lucigen MasterPure	Promega Wizard	NEB Monarch	Zymo Miniprep
<b>DNA yield (ng/ <math>\mu</math>L)</b>	16.66 $\pm$ 4.66	3.28 $\pm$ 1.00	13.37 $\pm$ 0.58	7.37 $\pm$ 1.62	7.35 $\pm$ 0.97	4.85 $\pm$ 0.48
<b>Absorbance ratio (A260/A280)</b>	1.74 $\pm$ 0.06	1.99 $\pm$ 0.15	2.1 $\pm$ 0.03	2.06 $\pm$ 0.13	1.74 $\pm$ 0.15	1.66 $\pm$ 0.17
<b>Proportion within range (1.8 – 2.1)</b>	14%	67%	50%	67%	42%	11%
<b>Absorbance ratio (A260/A230)</b>	0.70 $\pm$ 0.04	3.00 $\pm$ 0.73	2.89 $\pm$ 0.60	4.44 $\pm$ 1.27	1.2 $\pm$ 0.63	1.74 $\pm$ 0.41
<b>Proportion within range (2.0 – 3.0)</b>	0%	50%	59%	0%	8%	0%
<b>DNA Integrity Number</b>	1.97 $\pm$ 1.56	5.40 $\pm$ 0.50	7.40 $\pm$ 0.35	7.18 $\pm$ 0.45	6.08 $\pm$ 0.45	7.40 $\pm$ 0.25

346

347 The purity of extracted DNA was assessed using the 260/230 absorbance ratio. DNA  
 348 with a 260/230 absorbance ratio of 2.0 – 3.0 are considered pure and mostly free of  
 349 contaminants (such as phenols)<sup>28</sup>. Lucigen Masterpure had the largest proportion of

350 replicates (59%) within the suggested A260/A230 absorbance range, while the simple  
351 boiling method, the Zymo miniprep kit and the Promega Wizard kit failed to yield DNA  
352 within this purity range (**Figure 4B**).



**Figure 4** Absorbance ratios **(A)** A260/280 and **(B)** A260/230 indicating the presence of contamination and quality of DNA, respectively, of the extracted DNA extracted using six extraction methods. Technical (each sample extracted in

*triplicates) and experimental replicates (each extraction method performed three separate times) are plotted for each extraction kit (n = 36). The outliers are shown as points outside of the boxplot whiskers.*

353 Using all the measurement data, cost, ease of protocol (technical difficulty and  
354 equipment requirements), and time aspects (hands-on and total-protocol time) from  
355 the comparison of the five commercially available DNA extraction kits, a ranking matrix  
356 **(Table 2)** was produced based on the scores for each extraction method  
357 **(Supplementary Table 3)**. Simple boiling scored highly for yield, cost, and time but  
358 low for the purity scores (A260/230, A260/280 and DIN). Commercial kits performed  
359 better in this regard, with the Promega HMW and Qiagen DNeasy ranking highest for  
360 the A260/280 and the MasterPure ranking highest for the A260/230 absorbance ratio  
361 and the DIN score. All other rankings were variable between kits. The Lucigen  
362 MasterPure Complete DNA and RNA Purification Kit performed best for the extraction  
363 of high yield and quality DNA for sequencing to investigate single nucleotide variants  
364 of ESBL-EC in stool.

365  
366  
367  
368

**Table 2** Ranking of different DNA extraction methods, highest (1) to lowest (6).

DNA extraction kit	Cost	Time		Mean DNA yield (ng/ $\mu$ L)	DNA quality	Difficulty
		Hands-on	Total			
Qiagen DNeasy	5	2	3	2	5	3
Lucigen Masterpure	2	4	5	1	1	6
Promega HMW	5	4	5	2	1	5
NEB Monarch	3	1	2	2	4	2
Zymo Miniprep	4	2	3	2	1	3
Boiling	1	1	1	1	6	1

369

370 **Validation of workflow**

371 To investigate whether our workflow of a 4-hour pre-enrichment in BPW, plating on  
372 cefotaxime supplemented MacConkey and extraction using the MasterPure kit was  
373 sufficient for investigation of SNVs in closely related ESBL-EC strains, we performed  
374 both a control experiment where we processed an ESBL-negative stool spiked with a  
375 single clinical ESBL-EC strain (CAB17W) and assessed an ESBL-EC positive patient  
376 rectal swab using our workflow. Seven colonies from each of the cefotaxime  
377 supplemented MacConkey agar plates were then picked and sequenced. SNV  
378 analysis of the spiked stool confirmed that there were no SNVs between any of the  
379 single colony pick genomes as expected for a clonal spike (**Supplementary Table**  
380 **10**). Analysis of the ESBL-EC positive rectal swab revealed that the patient had two  
381 different ESBL-EC sequence types ST131 that had *bla*<sub>CTX-M-27</sub> and ST1193 that had  
382 *bla*<sub>CTX-M-15</sub>. SNV analysis of each ESBL-EC sequence type showed that there were 5  
383 SNV differences between the ST131 single picks (**Supplementary Table 11**) and 1  
384 SNV difference between one of the ST1193 picks and the other four single picks  
385 (**Supplementary Table 12**). We therefore concluded that our workflow was  
386 appropriate for SNV analysis of ESBL-EC from stool.

387

388 **Discussion**

389 Although *E. coli* is the dominating species of Enterobacteriaceae in the gut of healthy  
390 human adults, *E. coli* only constitute around 0.5% - 5% of the gut microbial community  
391 <sup>29</sup>. This makes it difficult for methods such as shotgun metagenomics to disentangle  
392 the diversity of pathogenic and non-pathogenic *E. coli* within a highly complex human  
393 gut microbiome without using costly very deep sequencing <sup>6,30</sup>. On the other end of the  
394 spectrum, the analysis of single colony picks from stool samples directly plated on



395 antibiotic supplemented agar, as is practice in many routine diagnostic laboratories, is  
396 insufficient to capture the intraspecies diversity of ESBL-EC, which can be substantial,  
397 as each colony would need to be analysed which would be extremely time-, cost- and  
398 labour-intensive<sup>31,32</sup>. Both methods are thus not feasible to implement as routine tool  
399 to monitor transmission of ESBL-EC in healthcare settings. Therefore, we investigated  
400 the impact of different microbiological approaches to optimise the recovery of ESBL-  
401 EC from human stool. We compared different methods at each stage of laboratory  
402 processing; pre-enrichment, isolation on selective agar, and DNA extraction, and were  
403 able to optimise a rapid and cost-effective approach for the recovery of ESBL-EC for  
404 targeted surveillance of ESBL-EC colonisation with the potential for sub-species  
405 resolution.

406

407 Numerous transmission studies have highlighted the challenge of capturing ESBL-EC  
408 variants present in small numbers in stool<sup>33–35</sup>. *E. coli* are only a small part of the  
409 diversity present within complex matrices and clinical samples (e.g., stool), increasing  
410 the likelihood of a test resulting in false negatives when stool is directly plated on  
411 supplemented agar<sup>36,37</sup>. To improve ESBL-EC detection for targeted surveillance,  
412 previous studies used pre-enrichment broth before plating on supplemented agar and  
413 were successful in recovering multiple ESBL-EC genotypes from human stool<sup>17</sup>.  
414 Indeed, we also showed that pre-enrichment is an effective tool to increase sensitivity  
415 for ESBL-EC detection from stool, thus improving the amount of ESBL-EC recovered  
416 on supplemented agar.

417

418 The standard practice of pre-enriching a sample for 18 to 24 hours is not conducive to  
419 rapid diagnosis and patient intervention<sup>38,39</sup>. A further concern with longer pre-

420 enrichment is the increased risk of creating competition with other lineages or species  
421 and skewing the relative abundance. Further, the potential of movement of mobile  
422 genetic elements (e.g. plasmids) can bias the recovery of the original strain<sup>40</sup>. We  
423 found that growth of ESBL-EC was variable and strain-dependent after an 18-hour  
424 pre-enrichment with and without the addition of an antibiotic supplement, suggesting  
425 that there is indeed potential for competition bias with longer incubation times.  
426 Therefore, we investigated a short pre-enrichment and found that a 4-hour pre-  
427 enrichment yielded sufficient growth for reliable downstream identification of ESBL-  
428 EC. Hence, we concluded that 4-hour pre-enrichment was not only preferable for  
429 consistent ESBL-EC recovery but also did not necessitate the addition of an antibiotic  
430 supplement and reduced the time and cost.

431

432 There are a variety of recommended supplemented agars available for ESBL-EC  
433 detection. Cefotaxime supplemented MacConkey agar is commonly used for  
434 surveillance studies and clinical microbiology laboratories since it is readily available  
435 and the cheapest of the three agars compared here<sup>10,11,41</sup>. However, chromogenic  
436 agar (CHROMagar ESBL<sup>42</sup>) is an increasingly popular alternative to MacConkey since  
437 it is effective at distinguishing between *E. coli* and other ESBL-producing  
438 Enterobacteriaceae using colour<sup>38,43,44</sup>. In addition to these two agars, we also tested  
439 ESBL-EC recovery on cefotaxime supplemented Membrane Lactose Glucuronide  
440 Agar (MLGA), which is commonly used for detecting faecal contamination in water  
441 sources<sup>45</sup>. We found that all three agars were effective in recovering from ESBL-EC  
442 from pre-enriched stool, allowing for flexibility with selective agar choice; we hence  
443 selected cefotaxime supplemented MacConkey as the most cost-effective in our  
444 setting.

445

446 We tested a wide variety of DNA extraction methods including commercial DNA  
447 purification kits and the boiling method as the simplest and cheapest method of DNA  
448 extraction from *E. coli*<sup>46</sup>. Since transmission studies require high resolution typing to  
449 clearly distinguish between two *E. coli* strains, high quality DNA is required.  
450 Commercially available kits provide standardised reagents, consumables and  
451 validated DNA extraction and purification methods. Depending on the extraction  
452 protocol, specialised equipment e.g. refrigerated centrifuges, skilled personnel, and  
453 an increased amount of time and cost are needed to extract DNA<sup>47</sup>. Taking this into  
454 consideration, along with the cost-per-sample, quality, and yield of DNA we compared  
455 six DNA extraction methods. While the boiling method was the simplest, cheapest,  
456 least time-consuming DNA extraction method with the highest yield and thus arguably  
457 of high value for highly time-sensitive applications or in cost-restricted setting, we show  
458 that the Lucigen MasterPure produced comparable DNA yield with much higher quality  
459 scores that were consistently reproducible.

460

461 Finally, we validated our optimised ESBL-EC recovery method using a spiked stool  
462 sample and a patient rectal swab. For the spiked stool sample, all sequenced 7  
463 colonies were identical and clonality was confirmed at single nucleotide resolution.  
464 With the patient rectal swab, we demonstrated the value of multiple colony picks  
465 through the recovery of two different ESBL-EC sequence types and the analysis of  
466 variation within each sequence type at single nucleotide resolution. The analysis of  
467 both samples at suggests that our method is suitable for studies aiming to infer  
468 transmission using SNV. While the methods we show here have focused on the  
469 recovery of ESBL-EC from stool, we suggest that these methods are also applicable

470 or easily adaptable for the recovery other drug resistant Enterobacteriaceae. ESBL-  
471 producing *Klebsiella* and *Enterobacter* species occupy a similar niche to ESBL-EC and  
472 are all recovered from stool through direct plating on supplemented agar<sup>10</sup>. With the  
473 increasing prevalence of drug resistant infections worldwide, it has become crucial to  
474 understand transmission pathways to put targeted preventative measures in place to  
475 interrupt transmission.

476

477 Our study demonstrates that a 4-hour pre-enrichment in either BPW or TS is effective  
478 for the recovery of ESBL-EC from stool without the addition of a third-generation  
479 cephalosporin and cefotaxime supplemented MacConkey, chromogenic agar and  
480 MLGA are all viable options for the recovery of pre-enriched ESBL-EC. The quality  
481 and quantity of DNA using different extraction kits is variable and not all yield high-  
482 quality DNA required for whole genome sequencing. The MasterPure Complete DNA  
483 and RNA Purification Kit produced a DNA yield that was comparable to the simple  
484 boiling method, but with higher quality scores that were consistently reproducible.  
485 Altogether this optimised workflow performs well for SNV analysis of ESBL-EC from  
486 stool and can thus be applied for genomic epidemiology and transmission studies.

487

## 488 **Ethics**

489 The healthy volunteers gave confidential consent for the use and storage of stool  
490 samples (LSTM Research Tissue Bank RTB/2022/007). The observational cohort  
491 study of hospital patients and care home residents in facilities in Liverpool was  
492 approved by the National Research Ethics Service Greater Manchester South ethics  
493 committee (ref: 22/NW/0343). Written informed consent was obtained from  
494 participants or consultees, as appropriate.

495

## 496 **Supplementary materials and data availability**

497 Supplementary Tables 1 – 12 and Supplementary Figures 1 - 3 are accessible in the  
498 supplementary material of this manuscript. The R scripts used to generate the figures,  
499 supplementary figures and data analyses in this manuscript are available from the  
500 GitHub repository [https://github.com/SarahGallichan/ESBL-EC\\_methods.git](https://github.com/SarahGallichan/ESBL-EC_methods.git).  
501 Protocols are available on Protocols.io  
502 ([dx.doi.org/10.17504/protocols.io.kxygxyk3dl8j/v](https://doi.org/10.17504/protocols.io.kxygxyk3dl8j/v)). Reads from sequenced isolates in  
503 this study are accessible in the Sequence Read Archive (SRA) using BioProject ID:  
504 PRJNA1095376.

505

## 506 **Funding**

507 This work was supported by iiCON (infection innovation consortium) via UK Research  
508 and Innovation (107136) and Unilever (MA-2021-00523N).

509

## 510 **Author contributions**

511 Conceptualisation and method development was done by S.G., S.F., M.M., E.H.,  
512 J.M.L., N.A.F., and F.E.G. Investigation was undertaken by S.G., S.F., E.P.-B, and  
513 C.M. Data analysis was done by S.G., J.M.L. and F.E.G. The original draft was  
514 prepared by S.G., E.H., J.M.L., N.A.F., and F.E.G and then reviewed and edited by all  
515 authors. Supervision was provided by E.H., J.M.L., N.A.F., and F.E.G.

516

## 517 **Acknowledgements**

518 We would like to thank Ross Gray for the illustrations used in Figure 1 of this  
519 manuscript, Finlay Hitchman for his assistance with the pre-enrichment broth

520 comparison work, and all the clinical staff and study participants that facilitated this  
521 study.

522 **References**

- 523 1. WHO publishes list of bacteria for which new antibiotics are urgently needed.  
524 [https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)  
525 [which-new-antibiotics-are-urgently-needed.](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)
- 526 2. Schwaber, M. J. & Carmeli, Y. Mortality and delay in effective therapy associated  
527 with extended-spectrum beta-lactamase production in Enterobacteriaceae  
528 bacteraemia: a systematic review and meta-analysis. *J Antimicrob Chemother*  
529 **60**, 913–920 (2007).
- 530 3. Melzer, M. & Petersen, I. Mortality following bacteraemic infection caused by  
531 extended spectrum beta-lactamase (ESBL) producing *E. coli* compared to non-  
532 ESBL producing *E. coli*. *Journal of Infection* **55**, 254–259 (2007).
- 533 4. Blom, A., Ahl, J., Månsson, F., Resman, F. & Tham, J. The prevalence of ESBL-  
534 producing Enterobacteriaceae in a nursing home setting compared with elderly  
535 living at home: a cross-sectional comparison. (2016) doi:10.1186/s12879-016-  
536 1430-5.
- 537 5. Bettelheim, K. A. *Escherichia coli* in the normal flora of humans and animals. in  
538 *Escherichia coli: mechanisms of virulence* (ed. Sussman, M.) 85–109  
539 (Cambridge University Press, Cambridge, 1997).
- 540 6. Foster-Nyarko, E. & Pallen, M. J. The microbial ecology of *Escherichia coli* in  
541 the vertebrate gut. *FEMS Microbiol Rev* **46**, (2022).
- 542 7. Alm, E. A. , W. S. T. , and G. D. M. The niche of *Escherichia coli*. in *In Population*  
543 *Genetics of Bacteria: A Tribute to Thomas S. Whittam* (eds. Walk, S. T. & Feng,  
544 P. C. H.) 68–89 (ASM Press, Washington, DC, USA, 2011).

- 545 8. Vollmerhausen, T. L. *et al.* Population structure and uropathogenic virulence  
546 associated genes of faecal *Escherichia coli* from healthy young and elderly  
547 adults. *J Med Microbiol* **60**, 574–581 (2011).
- 548 9. Balloux, F. *et al.* From Theory to Practice: Translating Whole-Genome  
549 Sequencing (WGS) into the Clinic. *Trends Microbiol* **26**, 1035–1048 (2018).
- 550 10. Public Health England. *UK Standards for Microbiology Investigations Detection*  
551 *of Enterobacteriaceae Producing Extended Spectrum  $\beta$ -Lactamases-*  
552 *Standards-for-Microbiology-Investigations-Smi-Quality-and-Consistency-in-*  
553 *Clinical-Laboratories.* (2016).
- 554 11. World Health Organization & Advisory Group on Integrated Surveillance on  
555 AMR. *WHO Integrated Global Surveillance on ESBL-Producing E. Coli Using a*  
556 *“One Health” Approach: Implementation and Opportunities.*  
557 <https://www.who.int/publications/i/item/9789240021402> (2021).
- 558 12. Bradford, P. A. Extended-spectrum beta-lactamases in the 21st century:  
559 characterization, epidemiology, and detection of this important resistance threat.  
560 *Clin Microbiol Rev* **14**, 933–951 (2001).
- 561 13. Naas, T., Cotellon, G., Ergani, A. & Nordmann, P. Real-time PCR for detection  
562 of blaOXA-48 genes from stools. *J Antimicrob Chemother* **68**, 101–104 (2013).
- 563 14. Wu, G. *et al.* Comparative Analysis of ESBL-Positive *Escherichia coli* Isolates  
564 from Animals and Humans from the UK, The Netherlands and Germany. *PLoS*  
565 *One* **8**, e75392 (2013).
- 566 15. Petty, N. K. *et al.* Global dissemination of a multidrug resistant *Escherichia coli*  
567 clone. *Proc Natl Acad Sci U S A* **111**, 5694–5699 (2014).



- 568 16. Toombs-Ruane, L. J. *et al.* Carriage of Extended-Spectrum-Beta-Lactamase-  
569 and AmpC Beta-Lactamase-Producing *Escherichia coli* Strains from Humans  
570 and Pets in the Same Households. *Appl Environ Microbiol* **86**, (2020).
- 571 17. Ludden, C. *et al.* Defining nosocomial transmission of *Escherichia coli* and  
572 antimicrobial resistance genes: a genomic surveillance study. *Lancet Microbe*  
573 **2**, e472–e480 (2021).
- 574 18. Sprouffske, K. & Wagner, A. Growthcurver: An R package for obtaining  
575 interpretable metrics from microbial growth curves. *BMC Bioinformatics* **17**, 1–4  
576 (2016).
- 577 19. Burz, S. D. *et al.* A Guide for Ex Vivo Handling and Storage of Stool Samples  
578 Intended for Fecal Microbiota Transplantation. *Sci Rep* **9**, (2019).
- 579 20. Dashti, A. A., Jadaon, M. M., Abdulsamad, A. M. & Dashti, H. M. Heat Treatment  
580 of Bacteria: A Simple Method of DNA Extraction for Molecular Techniques.  
581 *Kuwait Medical Journal* **41**, 117–122 (2009).
- 582 21. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for  
583 Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
- 584 22. Andrews, S. FastQC: A Quality Control tool for High Throughput Sequence  
585 Data. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (2010).
- 586 23. Hunt, M. *et al.* ARIBA: rapid antimicrobial resistance genotyping directly from  
587 sequencing reads. *Microb Genom* **3**, (2017).
- 588 24. Alcock, B. P. *et al.* CARD 2023: expanded curation, support for machine  
589 learning, and resistome prediction at the Comprehensive Antibiotic Resistance  
590 Database. *Nucleic Acids Res* **51**, D690–D699 (2023).
- 591 25. Wirth, T. *et al.* Sex and virulence in *Escherichia coli*: an evolutionary perspective.  
592 *Mol Microbiol* **60**, 1136–1151 (2006).

- 593 26. Croucher, N. J. *et al.* Rapid phylogenetic analysis of large samples of  
594 recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids*  
595 *Res* **43**, e15–e15 (2015).
- 596 27. R Core Team. *\_R: A Language and Environment for Statistical Computing\_*. *R*  
597 *Foundation for Statistical Computing, Vienna, Austria*. <[https://www.R-](https://www.R-project.org/)  
598 [project.org/](https://www.R-project.org/)> (2023).
- 599 28. DNA Purification | DNA Extraction Methods | Promega.  
600 [https://www.promega.co.uk/resources/guides/nucleic-acid-analysis/dna-](https://www.promega.co.uk/resources/guides/nucleic-acid-analysis/dna-purification/)  
601 [purification/](https://www.promega.co.uk/resources/guides/nucleic-acid-analysis/dna-purification/).
- 602 29. Tenailon, O., Skurnik, D., Picard, B. & Denamur, E. The population genetics of  
603 commensal *Escherichia coli*. *Nat Rev Microbiol* **8**, 207–217 (2010).
- 604 30. Huttenhower, C. *et al.* Structure, function and diversity of the healthy human  
605 microbiome. *Nature* 2012 486:7402 **486**, 207–214 (2012).
- 606 31. Stoesser, N. *et al.* Extensive Within-Host Diversity in Fecally Carried Extended-  
607 Spectrum-Beta-Lactamase-Producing *Escherichia coli* Isolates: Implications for  
608 Transmission Analyses. *J Clin Microbiol* **53**, 2122–2131 (2015).
- 609 32. Pallen, M. J. *et al.* Genomic diversity of *Escherichia coli* from healthy children in  
610 rural Gambia. doi:10.7717/peerj.10572.
- 611 33. Aguilar-Bultet, L. *et al.* Within-host genetic diversity of extended-spectrum beta-  
612 lactamase-producing Enterobacterales in long-term colonized patients. *Nature*  
613 *Communications* 2023 14:1 **14**, 1–14 (2023).
- 614 34. Adler, A. *et al.* Transmission dynamics of ESBL-producing *Escherichia coli*  
615 clones in rehabilitation wards at a tertiary care centre. *Clinical Microbiology and*  
616 *Infection* **18**, E497–E505 (2012).

- 617 35. Duval, A. *et al.* Close proximity interactions support transmission of ESBL-K.  
618 pneumoniae but not ESBL-E. coli in healthcare settings. *PLoS Comput Biol* **15**,  
619 e1006496 (2019).
- 620 36. Peto, L. *et al.* Selective culture enrichment and sequencing of feces to enhance  
621 detection of antimicrobial resistance genes in third-generation cephalosporin  
622 resistant Enterobacteriaceae. *PLoS One* **14**, (2019).
- 623 37. Huttenhower, C. *et al.* Structure, function and diversity of the healthy human  
624 microbiome. *Nature* **486**, 207–214 (2012).
- 625 38. Rondinaud, E., Ruppé, E., Matheron, S., Lucet, J. C. & Armand-Lefevre, L.  
626 Screening methods for intestinal carriage of multidrug-resistant  
627 Enterobacterales: interest of enrichment broth. *Diagn Microbiol Infect Dis* **97**,  
628 115079 (2020).
- 629 39. Jazmati, T., Hamprecht, A. & Jazmati, N. Comparison of stool samples and  
630 rectal swabs with and without pre-enrichment for the detection of third-  
631 generation cephalosporin-resistant Enterobacterales (3GCREB).  
632 doi:10.1007/s10096-021-04250-1/Published.
- 633 40. Conrad, C. C., Stanford, K., McAllister, T. A., Thomas, J. & Reuter, T.  
634 Competition during enrichment of pathogenic Escherichia coli may result in  
635 culture bias. <https://doi.org/10.1139/facets-2016-0007> **1**, 114–126 (2016).
- 636 41. Jacob, M. E., Keelara, S., Aidara-Kane, A., Matheu Alvarez, J. R. & Fedorka-  
637 Cray, P. J. Optimizing a Screening Protocol for Potential Extended-Spectrum  $\beta$ -  
638 Lactamase Escherichia coli on MacConkey Agar for Use in a Global  
639 Surveillance Program. *J Clin Microbiol* **58**, (2020).
- 640 42. CHROMagar™ ESBL - Chromagar.  
641 <https://www.chromagar.com/en/product/chromagar-esbl/>.

- 642 43. El-Jade, M. R. *et al.* ESBL Detection: Comparison of a Commercially Available  
643 Chromogenic Test for Third Generation Cephalosporine Resistance and  
644 Automated Susceptibility Testing in Enterobacteriaceae. *PLoS One* **11**,  
645 e0160203 (2016).
- 646 44. Réglie-Poupet, H. *et al.* Performance of chromID ESBL, a chromogenic medium  
647 for detection of Enterobacteriaceae producing extended-spectrum  $\beta$ -  
648 lactamases. *J Med Microbiol* **57**, 310–315 (2008).
- 649 45. Sartory, D. P. & Howard, L. A medium detecting  $\beta$ -glucuronidase for the  
650 simultaneous membrane filtration enumeration of *Escherichia coli* and coliforms  
651 from drinking water. *Lett Appl Microbiol* **15**, 273–276 (1992).
- 652 46. Shah DH, S. S. B. T. C. D. *Molecular Detection of Food Borne Pathogens*.  
653 (Taylor & Francis Group, CRC Press, USA, 2010).
- 654 47. Barbosa, C., Nogueira, S., Gadanho, M. & Chaves, S. DNA extraction: finding  
655 the most suitable method. *Molecular Microbial Diagnostic Methods: Pathways  
656 to Implementation for the Food and Water Industries* 135–154 (2016)  
657 doi:10.1016/B978-0-12-416999-9.00007-1.  
658